(PS6-C52) Development of Japanese Version of the Brief Assessment of Distress About Pain

Measuring negative psychological states associated with pain is critical for identifying vulnerable individuals. The Brief Assessment of Distress about Pain (BADP) is a 4-item self-report scale that was originally developed in the United States to assess anxiety, fear, depression related to pain, and an overall negative affect toward the experience of pain. Because of its ease of administration, scoring, and interpretation, the BADP is considered as a useful instrument for healthcare providers and researchers working with pain patients. Thus, the current study aimed to develop the Japanese version of the BADP (BADP-JP). The original version was forward- and back-translated between English and Japanese. Along with the BADP-JP, information on demographic and pain experience and responses to the Japanese version of the Fear of Pain Questionnaire-9 (FPQ-9-JP), the Japanese version of the Pain Catastrophizing Scale (PCS-JP), the Japanese version of the Anxiety Sensitivity Index-3 (ASI-3-JP), and the Japanese version of the Center for Epidemiologic Studies Depression Scale (CES-D-JP) were collected from 348 Japanese undergraduates through an online survey using Qualtrics. The mean age of participants was 19.45 years (SD = 1.16) and 64.4% was female. Internal consistency of the BADP-JP total score was sufficiently high (α = .84). Intra-scale correlation coefficients indicated that the BADP-JP anxiety item and the BADP-JP fear item correlated strongly (r = .70), while the other items moderately correlated with each other (.48 < r < .59). The correlation between total scores on the BADP-JP and the PCS-JP was moderate (r = .55), suggesting convergent validity. On the other hand, three of the four single-item subscales, the BADP-JP anxiety, fear, and depression, had very weak to weak correlations with other scales measuring similar constructs (.09 < r < .32). The Confirmatory Factor Analysis for the one-factor model of the BADP-JP showed a poor fit with the Japanese sample due to the high RMSEA (GFI = .98, CFI = .97, RMSEA = .15). Twenty-five (7.2%) participants experiencing chronic pain scored higher than the other participants on the BADP total and subscales, indicating concurrent validity. These results suggest that the BADP-JP total score has potential for dissemination and utility for routine and/or brief screening in both clinical and research situations, while the validity of single-item subscales needs further investigation in diverse participants, including a clinical sample.